A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Subjects With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02964104
• Other study ID #: NN1436-4314
• Secondary ID: 2016-000436-18U1
• Status: Completed
• Phase: Phase 1
• Start date: November 15, 2016
• Est. completion date: December 12, 2017

Study information

• Verified date: August 2021
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of insulin 287 in subjects with type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 12, 2017
• Est. primary completion date: December 12, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Male or female, age between 18 and 64 years (both inclusive) at the time of signing informed consent.

• Subject who is considered to be generally healthy (with the exception of conditions associated with diabetes mellitus), based on the medical history, physical examination, and the results of vital signs, ECG and laboratory safety tests, as judged by the investigator.

• Body mass index between 20.0 and 34.9 kg/m^2 (both inclusive).

• Type 2 diabetes mellitus (as diagnosed clinically) for =12 months (365 days).

• No change in insulin treatment regimen during the last 90 days prior to screening.

• Current total daily insulin treatment between 0.3 and 1.0 (I) U/kg/day (both inclusive).

Exclusion Criteria:

• Known or suspected hypersensitivity to trial products or related products.

• Female who is pregnant, breast-feeding, or intending to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by regulation or practice)(highly effective contraceptive methods are considered those with a failure rate less than 1% undesired pregnancies per year including surgical sterilisation,hormonal intrauterine devices (coil), oral hormonal contraceptives, sexual abstinence or a surgically sterilised partner). Females who are not postmenopausal can participate in the study if they use adequate contraceptive methods. Postmenopausal is defined as women aged <52 years and being amenorrheic for more than one year with serum follicle stimulating hormone (FSH level >40 IU/L or aged = 52 years and being amenorrheic for less than one year and with serum FSH level > 40 IU/L or aged = 52 years being amenorrheic for more than one year.

• Receipt of any investigational medicinal product within 3 months before the screening visit of this trial.

• History of deep leg vein thrombosis or repeated episodes of deep leg vein thrombosis in 1st degree relatives (parents, siblings or children) as judged by the investigator.

• Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days.

• Use of oral antidiabetic drugs (OADs) or GLP-1 receptor agonists (e.g. exenatide, liraglutide) within 3 months prior to screening.

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Insulin icodec
Administered once weekly subcutaneously (s.c., under the skin) for 35 days
• placebo
Administered once daily subcutaneously for 35 days
• insulin degludec
Administered once daily subcutaneously for 35 days
• placebo
Administered once weekly subcutaneously for 35 days

Locations

Country	Name	City	State
Germany	Novo Nordisk Investigational Site	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Nishimura E, Pridal L, Glendorf T, Hansen BF, Hubálek F, Kjeldsen T, Kristensen NR, Lützen A, Lyby K, Madsen P, Pedersen TÅ, Ribel-Madsen R, Stidsen CE, Haahr H. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of treatment emergent adverse events (TEAE)		From the first trial product administration at day 1 until completion of the post-treatment follow-up visit (day 68 - 79)
Secondary	AUCI287,t,SS, area under the steady-state serum insulin 287 concentration-time curve		During one dosing interval at steady-state from 0 to 168 hours after last dose (day 29)
Secondary	AUCGIR,0-24h,SS, area under the glucose infusion rate-time curve at steady state		At day 30 and day 35